AVADEL PHARMACEUTICALS PLC 4

Director-level insider Linda Palczuk tendered 78,905 Avadel ordinary shares and cancelled options over 266,000 shares into $21.00-per-share cash consideration plus CVRs in connection with Avadel’s acquisition by Alkermes.

On February 12, 2026, reporting person Linda Palczuk disposed of all 78,905 Avadel Pharmaceuticals plc ordinary shares at $21.00 per share in cash plus a contingent value right (CVR) of up to $1.50 per share, pursuant to the closing of Avadel’s acquisition by Alkermes plc via an Irish scheme of arrangement. At the same effective time, all of her outstanding Avadel stock options held through a revocable trust—covering 60,000 shares at a $2.03 strike, 42,000 shares at $8.48, 42,000 shares at $8.07, 42,000 shares at $4.79, 33,000 shares at $14.10, 11,000 shares at $16.32, 25,000 shares at $10.93, and 11,000 shares at $10.83—were cancelled and converted into the right to receive cash equal to the intrinsic value based on the $21.00 cash consideration plus one CVR per underlying share, resulting in an exit from equity ownership in Avadel in connection with the change‑of‑control transaction.

Filing Facts

CIK

1012477

Ticker

AVDL

Form

4

Source Type

sec

Accession

0001104659-26-014446

Alert Tier

6